Who are NL003's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): vemurafenib + HD IL-2, Basiliximab, Tacrolimus, MMF, Prednisolon, IL-2 (interleukin 2), histamine dihydrochloride and IL-2, anti-CD25 rhMAb, Basiliximab treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nl003.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

NL003 — Competitive Intelligence Brief

NL003 (NL003) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine / IL-2 receptor agonist. Area: Oncology.

phase 3 Cytokine / IL-2 receptor agonist IL-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NL003 (NL003) — Beijing Northland Biotech. Co., Ltd.. NL003 is a recombinant human IL-2 mutein that selectively activates IL-2 receptor signaling to enhance immune cell proliferation and anti-tumor activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NL003 TARGET	NL003	Beijing Northland Biotech. Co., Ltd.	phase 3	Cytokine / IL-2 receptor agonist	IL-2 receptor
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor
Basiliximab, Tacrolimus, MMF, Prednisolon	Basiliximab, Tacrolimus, MMF, Prednisolon	University Hospital Freiburg	marketed	Immunosuppressive combination regimen	IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone)
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
anti-CD25 rhMAb	anti-CD25 rhMAb	Peking University People's Hospital	marketed	CD25 antagonist monoclonal antibody	CD25 (IL-2 receptor alpha chain)
Basiliximab treatment	Basiliximab treatment	Nantes University Hospital	marketed	Monoclonal antibody; IL-2 receptor antagonist	CD25 (IL-2 receptor alpha chain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine / IL-2 receptor agonist class)

Beijing Northland Biotech. Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NL003 — Competitive Intelligence Brief. https://druglandscape.com/ci/nl003. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab